Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant erdafitinib with or without cetrelimab for FGFR-altered cisplatin-ineligible muscle-invasive bladder cancer
ISRCTN14498712Phase 2Active, not recruiting
- Sponsor
- SOGUG
- Start
- Jan 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of erdafitinib and cetrelimab in bladder cancer (2 arms), sponsored by SOGUG. Primary endpoints: Pathological complete response and Pathological downstaging to less than ypT2. Started Jan 2024; status: active, not recruiting.
02
Drugs
erdafitinibcetrelimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ISRCTN14498712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14498712.